Evidence map›Paper›PMID 39944081›Full record

ArticleFrontiers in cellular and infection microbiology2024

Cryptic transmission of a SARS-CoV-2 variant detected by wastewater surveillance in Panama.

Melissa Gaitán, Yamitzel Zaldivar, Michelle Hernandez, Jessica Góndola, Oris Chavarría, Brechla Moreno, Danilo Franco, Rodrigo DeAntonio, Santiago Mirazo, Florencia Cancela and 4 more

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Melissa GaitánDepartment of Research in Virology and Biotechnology, Gorgas Memorial Institute for Health Studies, Panama City, Panama.
Yamitzel ZaldivarDepartment of Research and Surveillance of Biologic Risk 3, Gorgas Memorial Institute for Health Studies, Panama City, Panama.
Michelle HernandezDepartment of Research and Surveillance of Biologic Risk 3, Gorgas Memorial Institute for Health Studies, Panama City, Panama.
Jessica GóndolaDepartment of Genomics and Proteomics, Gorgas Memorial Institute for Health Studies, Panama City, Panama.
Oris ChavarríaDepartment of Genomics and Proteomics, Gorgas Memorial Institute for Health Studies, Panama City, Panama.
Brechla MorenoDepartment of Research in Virology and Biotechnology, Gorgas Memorial Institute for Health Studies, Panama City, Panama.
Danilo FrancoDepartment of Research in Virology and Biotechnology, Gorgas Memorial Institute for Health Studies, Panama City, Panama.
Rodrigo DeAntonioCentro de Vacunacion e Investigacion CEVAXIN, Panama City, Panama.
Santiago MirazoUnidad Académica de Bacteriología y Virología, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Florencia CancelaUnidad Académica de Bacteriología y Virología, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Maria Eugenia BarnettClinical Research Unit, Gorgas Memorial Institute for Health Studies, Panama City, Panama.
Alexander A MartinezDepartment of Genomics and Proteomics, Gorgas Memorial Institute for Health Studies, Panama City, Panama.
Juan Miguel PascaleClinical Research Unit, Gorgas Memorial Institute for Health Studies, Panama City, Panama.
Sandra López-VergèsDepartment of Research in Virology and Biotechnology, Gorgas Memorial Institute for Health Studies, Panama City, Panama.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic highlighted the critical role of viral genomic surveillance, prompting numerous countries to enhance their monitoring systems for acute respiratory infections (ARIs), especially influenza-like illnesses (ILIs). Given the significance of asymptomatic cases in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission, cases often undetected by the ILI surveillance, a more comprehensive approach was essential to track the circulation of SARS-CoV-2 variants in the population. In response, many countries swiftly adopted wastewater surveillance, which allowed the early detection of SARS-CoV-2 variants before they were identified through molecular characterization from confirmed clinical cases. In this report, we detail the implementation of SARS-CoV-2 wastewater genomic surveillance in Panama during the first half of 2024. Wastewater samples were collected monthly in duplicate at two collection points from three districts of Panama city metropolitan area for testing by SARS-CoV-2 RT-qPCR, and positive samples were analyzed by next-generation sequencing to identify sublineages. A total of 36 wastewater samples and 822 samples obtained through the clinical surveillance were analyzed for molecular detection and sequencing. Sublineages detected by wastewater surveillance were compared to those detected by clinical surveillance for the same period of time. Wastewater surveillance allowed the identification of the Omicron sublineage JN.1.16.1 in the capital city and its surroundings, which was not detected by the clinical surveillance in the country, despite its global circulation. This highlights the critical need to sustain both genomic surveillance programs beyond the pandemic in countries like Panama that serve as pivotal exchange hubs.

Indexed as

COVID-19SARS-CoV-2WastewaterWastewater-Based Epidemiological MonitoringGenome, ViralHigh-Throughput Nucleotide SequencingHumansPanamaPhylogenyRNA, ViralRNA, ViralWastewatercomplete genomesgenomic surveillancemolecular detectionoutbreakSARS-CoV-2variantwastewater surveillance

Identifiers

PMID39944081
PMCPMC11813908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.